US 7,585,676 B2
	Retroviral vector
Kyriacos Mitrophanous, Oxford (United Kingdom); Mary Collins, London (United Kingdom); Yasuhiro Takeuchi, London (United Kingdom); and Yasuhiro Ikeda, London (United Kingdom)
Assigned to Oxford Biomedica (UK) Limited, Oxford (United Kingdom)
Filed on Jan. 29, 2008, as Appl. No. 12/21,343.
Application 12/021343 is a continuation of application No. 10/654537, filed on Sep. 02, 2003, granted, now 7,351,585.
Claims priority of provisional application 60/417673, filed on Oct. 09, 2002.
Claims priority of application No. 0220467.5 (GB), filed on Sep. 03, 2002.
Prior Publication US 2008/0286869 A1, Nov. 20, 2008
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/10 (2006.01); C12N 15/48 (2006.01); C12N 15/49 (2006.01); C12N 15/63 (2006.01); C12N 15/64 (2006.01); C12N 15/867 (2006.01); A61K 48/00 (2006.01)

U.S. Cl. 435—455  [435/325; 435/320.1; 435/366]

18 Claims

1. A method for producing a stable lentiviral packaging cell comprising transfecting a cell with a retroviral vector comprising a nucleotide sequence encoding lentiviral Gag-Pol, wherein the retroviral vector is of different viral origin than a lentivirus, and wherein the lentiviral packaging cell stably produces lentiviral Gag-Pol continuously for at least 3 months.